The components of income tax expense (benefit) for the years ended December 31, 2022, 2021 and 2020 are as follows:


(In thousands)	2022			2021			2020
Current
Federal	$	4,572		$	11		$	(10,574	)
State		88			(63	)		(329	)
International		(4,347	)		4,166			3,635
Total Current		313			4,114			(7,268	)

Deferred
Federal		(47,429	)		—			—
State		(6,776	)		—			—
International		(8,183	)		(1,784	)		(1,356	)
Total Deferred		(62,388	)		(1,784	)		(1,356	)
Total Income Tax (Benefit) Expense	$	(62,075	)	$	2,330		$	(8,624	)

The effective income tax rate differs from the federal statutory rate due to the following:


	2022			2021			2020
Tax provision computed at the federal statutory rate		21.00	%		21.00	%		21.00	%
State income tax provision, net of federal benefit		2.60			13.33			11.10
Federal research credits		6.74			53.77			57.63
Foreign taxes		6.29			(4.69	)		(17.83	)
Tax-exempt income		0.21			3.75			1.93
Change in valuation allowance		63.92			(75.26	)		44.79
Non-deductible transaction costs		(2.74	)		(39.48	)		—
Foreign tax credits		(0.40	)		0.14			17.90
Stock-based compensation		(2.09	)		10.74			(23.36	)
Withholding taxes		0.03			0.14			(20.83	)
Alabama law change		—			(25.39	)		—
Impact of CARES Act		—			—			45.65
Return to accrual		0.24			9.48			—
Global intangible low-taxed income ("GILTI")		(8.08	)		(4.29	)		(0.49	)
Other, net		(0.24	)		(0.19	)		0.56
Effective Tax Rate		87.48	%		(36.95	)%		138.05	%

(Loss) income before expense (benefit) for income taxes for the years ended December 31, 2022, 2021 and 2020 is as follows:


(In thousands)	2022			2021			2020
U.S. entities	$	(33,720	)	$	(14,982	)	$	(12,833	)
International entities		(37,243	)		8,677			6,587
Total	$	(70,963	)	$	(6,305	)	$	(6,246	)

(Loss) income before expense (benefit) for income taxes for international entities reflects (loss) income based on statutory transfer pricing agreements. This amount does not correlate to consolidated international revenue, which occurs from our U.S. entity.

Deferred income taxes on the Consolidated Balance Sheets result from temporary differences between the amount of assets and liabilities recognized for financial reporting and tax purposes. The significant components of current and non-current deferred taxes as of December 31, 2022 and 2021 consist of the following:


(In thousands)	2022			2021
Deferred tax assets:
Inventory	$	5,818		$	9,538
Accrued expenses		7,865			3,851
Deferred compensation		5,792			7,027
Stock-based compensation		1,373			1,469
Uncertain tax positions related to state taxes and related interest		102			124
Pensions		5,952			6,061
Foreign losses		4,744			2,862
State losses and credit carry-forwards		3,516			5,914
Federal loss and research carry-forwards		64,995			21,606
Lease liabilities		4,093			1,471
Capitalized research and development expenditures		31,248			9,349
Investments		160			—
Valuation allowance		(5,201	)		(50,564	)
Total Deferred Tax Assets		130,457			18,708

Deferred tax liabilities:
Property, plant and equipment		(8,982	)		(3,590	)
Intellectual property		(108,671	)		(3,230	)
Right of use lease assets		(6,594	)		(1,459	)
Investments		—			(1,350	)
Total Deferred Tax Liabilities		(124,247	)		(9,629	)
Net Deferred Tax Assets	$	6,210		$	9,079

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was signed into law. Subsequently, the Internal Revenue Service (“IRS”) released its final GILTI regulations on July 9, 2020. The passage of the CARES Act and subsequent issuance of the GILTI final regulations together resulted in the Company’s recognition of a tax benefit in the amount of $10.8 million during 2020, $7.9 million of which related to the utilization of deferred tax assets which had previously been offset with a valuation allowance and $2.9 million primarily related to the tax rate differential on carrying back losses from 2018 and 2019 tax years to prior years in which the U.S. Corporate tax rate was 35% versus the current 21% federal tax rate.

On February 12, 2021, the Alabama Business Tax Competitiveness Act (the "Act") was signed into law. As a result of the Act, we recognized an expense of $1.6 million in the three months ended March 31, 2021 related to the revaluation of our deferred tax assets, which was offset by changes in our valuation allowance previously recorded against our domestic deferred tax assets.

During the three months ended September 30, 2021, Management decided to pursue a claim for refund related to the revocation of our IRC Section 59(e) election that was made on our originally filed 2018 U.S. federal tax return. The Company filed a related carryback claim of net operating losses generated in 2018 to prior years as allowed under the CARES Act that was passed in 2020. An IRS Section 59(e) election is generally non-revocable except in cases for which IRS Commissioner’s approval is given. Approval is granted only in rare and unusual circumstances. We filed a private letter ruling (“PLR”) request to revoke our election. During the three months ended December 31, 2021, a response to our PLR was published denying our request to revoke the previously made 59(e). As a result of these filings, and Management’s position to pursue them through appeals, we have established a receivable in the amount of $15.2 million and a deferred tax asset related to additional research and development credit carryforward in the amount of $1.8 million that would be available if our revocation request is successful, offset with an uncertain tax liability of $17.0 million.

As of December 31, 2022 and 2021, non-current deferred taxes reflected deferred taxes on net unrealized gains and losses on available-for-sale investments and deferred taxes on unrealized losses in our pension plan. The net change in non-current deferred taxes associated with these items, which resulted in a deferred tax expense of $2.0 million and $1.6 million in 2022 and 2021, respectively, was recorded as an adjustment to other comprehensive (loss) income, presented in the Consolidated Statements of Comprehensive (Loss) Income.

The Company continually reviews the adequacy of its valuation allowance and recognizes the benefits of deferred tax assets only as the reassessment indicates that it is more likely than not that the deferred tax assets will be recognized in accordance with ASC 740, Income Taxes. Our assessment of the realizability of our deferred tax assets includes the evaluation of evidence, some of which requires significant judgment, including historical operating results, the evaluation of a three-year cumulative income position, future taxable income projections and tax planning strategies. Should management’s conclusion change in the future and additional valuation allowance or a partial or full release of the valuation allowance become necessary, it could have a material effect on our consolidated financial statements. During the fourth quarter of 2022, after considering all quantitative and qualitative evidence, including our cumulative income position, historical operating performance and future income projections, we have determined that the positive evidence overcame the negative evidence and have concluded that it is more likely than not that a substantial portion of our U.S. federal and certain other state deferred tax assets were realizable. As a result we have released the majority of our valuation allowance against those assets.

As of December 31, 2022 and 2021, the Company had gross deferred tax assets totaling $11.4 million offset by a valuation allowance totaling $5.2 million and gross deferred tax assets totaling $59.6 million offset by a valuation allowance of $50.6 million, respectively. Of the current valuation allowance, $3.2 million was established against our domestic deferred tax assets and the remaining $2.0 million is related to foreign net operating loss and research and development credit carryforwards where we lacked sufficient activity to realize those deferred tax assets. The change in our valuation allowance for the year ending December 31, 2022 was a decrease of $45.4 million. The change in the valuation allowance was primarily related to the previously mentioned release of the valuation allowance in the fourth quarter of 2022. The large increase during the year in our international deferred tax liabilities was primarily related to purchase price accounting, partially offset with acquired deferred tax assets as a result of the ADVA acquisition, that was completed in the third quarter of 2022.

Supplemental balance sheet information related to deferred tax assets (liabilities) as of December 31, 2022 and 2021 were as follows:


	December 31, 2022
(In thousands)	Deferred Tax Assets (Liabilities)			Valuation Allowance			Deferred Tax Assets (Liabilities), net
Domestic	$	61,726		$	(3,177	)	$	58,549
International		(50,315	)		(2,024	)		(52,339	)
Total	$	11,411		$	(5,201	)	$	6,210


	December 31, 2021
(In thousands)	Deferred Tax Assets		Valuation Allowance			Deferred Tax Assets, net
Domestic	$	48,265	$	(48,265	)	$	—
International		11,378		(2,299	)		9,079
Total	$	59,643	$	(50,564	)	$	9,079

As of December 31, 2022 and 2021, the deferred tax assets for foreign and domestic loss carry-forwards, research and development tax credits, unamortized research and development costs and state credit carry-forwards totaled $104.5 million and $39.7 million, respectively. As of December 31, 2022, $21.8 million of these deferred tax assets will expire at various times between 2023 and 2038. The remaining deferred tax assets will either amortize through 2038 or carryforward indefinitely.

As of December 31, 2022 and 2021, respectively, our cash and cash equivalents were $108.6 million and $56.6 million and short-term investments were $0.3 million and $0.4 million, which provided available short-term liquidity of $108.9 million and 57.0 million. Of these amounts, our foreign subsidiaries held cash of $86.3 million and $47.7 million, respectively, representing approximately 79% and 84% of available short-term liquidity, which is used to fund ongoing liquidity needs of these subsidiaries. As part of our restructuring plan, the Company’s assertion on being indefinitely reinvested changed in a particular jurisdiction in a previous year. The Company has a withholding tax liability of $0.4 million and $0.7 million as of December 31, 2022 and 2021, respectively. The Company maintains its assertion in all other jurisdictions that it is indefinitely reinvesting its funds held in foreign jurisdictions outside of the U.S., except to the extent any of these funds can be repatriated without withholding tax. However, if all of these funds were repatriated to the U.S., or used for U.S. operations, certain amounts could be subject to tax. Due to the timing and circumstances of repatriation of such earnings, if any, it is not practicable to determine the amount of funds subject to unrecognized deferred tax liability.

During 2022, 2021 and 2020, no income tax benefit or expense was recorded for stock options exercised as an adjustment to equity.

The change in the unrecognized income tax benefits for the years ended December 31, 2022, 2021 and 2020 were as follows:


(In thousands)	2022			2021			2020
Balance at beginning of period	$	17,836		$	1,078		$	1,487
Increases for tax position related to:
Prior years		—			17,025			4
Current year		123			136			165
Decreases for tax positions related to:
Prior years		(13	)		(27	)		—
Expiration of applicable statute of limitations		(61	)		(376	)		(578	)
Balance at end of period	$	17,885		$	17,836		$	1,078

As of December 31, 2022, 2021 and 2020, our total liability for unrecognized tax benefits was $17.9 million, $17.8 million and $1.1 million, respectively, of which $17.9 million, $17.8 million and $1.0 million, respectively, would reduce our effective tax rate if we were successful in upholding all of the uncertain positions and recognized the amounts recorded. We classify interest and penalties recognized on the liability for unrecognized tax benefits as income tax expense. As of December 31, 2022, 2021 and 2020, the balances of accrued interest and penalties were $0.1 million, $0.2 million and $0.3 million, respectively.

We do not anticipate a single tax position generating a significant increase or decrease in our liability for unrecognized tax benefits within 12 months of this reporting date, unless a resolution is reached regarding the appeal of our PLR denial noted above. We file income tax returns in the U.S. for federal and various state jurisdictions and several foreign jurisdictions. We are not currently under audit by the Internal Revenue Service. Generally, we are not subject to changes in income taxes by any taxing jurisdiction for the years prior to 2018.